170098-39-2

Basic information

• Product Name: methyl (3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinepropanoate
• CAS NO: 170098-39-2
• Molecular Formula: C₁₇H₂₅NO₃
• Molecular Weight: 291.38500
• Mol File: 170098-39-2.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: methyl (3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinepropanoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl (3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinepropanoate(170098-39-2)
• EPA Substance Registry System: methyl (3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinepropanoate(170098-39-2)

Safety Data

• Hazardous Substances Data: 170098-39-2(Hazardous Substances Data)

Usage

General Description

The chemical methyl (3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinepropanoate is a piperidine derivative with a methyl ester group and a hydroxyphenyl group attached to the piperidine ring. It belongs to a class of compounds known as piperidine propanoates and is used in the pharmaceutical industry as an intermediate in the synthesis of various drugs. methyl (3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinepropanoate has potential applications as a pharmaceutical agent due to its structural features and biological activities. The specific stereochemistry of the molecule, indicated by the (3R,4R) designation, may be important for its biological function and potential pharmacological properties. Further research and development of this compound may lead to the discovery of new drug candidates for various medical conditions.

Upstream product

• 149541-62-8 C₁₉H₂₉NO₄ 
• 149541-62-8 cis-(-)-carbonic acid ethyl 1,3-dimethyl-4-[3-(l-methylethoxy)phenyl]-4-piperidinyl ester 
• 145340-44-9 1,3-dimethyl-4-[3-(propan-2-yloxy)phenyl]-4-piperidinol 
• 4629-80-5 1,3-dimethyl-4-piperidinone 
• 131738-73-3 3-(isopropyloxy)phenylbromide 
• 1184775-81-2 C₁₇H₂₇NO*C₂₀H₁₈O₈ 
• 143919-32-8 (R)-1,2,3,4-tetrahydro-1,3-dimethyl-4-<3-(1-methylethoxy)phenyl>pyridine 
• 143919-34-0 (3R,5R)-1,3,4-trimethyl-4-<3-(1-methylethoxy)phenyl>piperidine 
• 145678-86-0 (3R,4R)-3,4-dimethyl-4-<3-(1-methylethoxy)phenyl>piperidinecarboxylic acid phenyl ester 
• 119193-19-0 3-[(3R,4R)-3,4-dimethylpiperidin-4-yl]phenol 
• 292638-85-8 acrylic acid methyl ester 
• 312329-70-7 4-(3-hydroxyphenyl)-trans-3,4-dimethylpiperidine 

Downstream Products

• 156130-41-5 ADL 08-0011 
• 145603-86-7 (+)-<<2'(S)-<<4(R)-3-(hydroxyphenyl)-3(R),4-dimethyl-1-piperidinyl>methyl>-1-oxo-3-phenylpropyl>amino>acetic acid 2-methylpropyl ester 
• 156053-89-3 Entereg 
• 156130-44-8 2‐((R)‐2‐benzyl‐3‐((3R,4R)‐4‐(3‐hydroxyphenyl)‐3,4‐dimethylpiperidin‐1‐yl)propanamido)acetic acid 
• 170098-29-0 methyl (αS,3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-α-(phenylmethyl)-1-piperidinepropanoate 
• 808102-09-2 C₁₆H₂₃NO₃ 

Relevant articles and documents

Synthesis and characterization of all possible diastereoisomers of alvimopan

Isolation of all possible diastereomers of alvimopan 1 was found to be challenging. In order to perform cut off studies during analytical method development, it was mandatory to synthesize and characterize all the diastereomeric impurities. Here in, our efforts toward the synthesis and isolation of alvimopan (1) diastereomers are discussed.

Compositions containing opioid antagonist

Compositions containing opioid antagonists, particularly alvimopan and its active metabolite, with improved solubility and bioavailability for oral or parenteral administration, injectable dosage formulations, kits, and methods of making and using same are disclosed. In preferred embodiments, invention provides injectable formulations containing opioid antagonists, particularly alvimopan and its active metabolite, having low solubility that may be readily prepared, are stable during storage, and provide maximum levels of opioid antagonists when administered parenterally, particularly via injection. The results are achieved by a combination of processing techniques and component selection.

Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates

This invention relates to a process for preparing certain 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates, intermediates, and congeners. Finally, the invention provides new 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates with formulations and me